论文部分内容阅读
目的:探讨TUBB3 mRNA表达对紫杉醇化疗晚期非小细胞肺癌患者疗效影响。方法:对我院收治的100例晚期非小细胞肺癌患者根据其TUBB3 mRNA表达情况将其分为阳性组55例和阴性组45例,对两组患者均采用紫杉醇联合顺铂进行治疗,分析两组患者的临床资料以及预后。结果:两组患者的临床资料无明显差异性,而阴性组患者在客观缓解率、部分缓解率、疾病进展率、总生存时间以及至肿瘤进展时间均优于对照组(P<0.05)。阳性组在性别、年龄、淋巴结转移、TNM分期的比较中无差异,而在病理分型中(鳞癌/腺癌)的比较中存在显著性差异。结论:TUBB3 mRNA阴性表达的患者其采用紫杉醇联合顺铂进行治疗可明显延长患者生存时间。
Objective: To investigate the effect of TUBB3 mRNA expression on the efficacy of paclitaxel chemotherapy in patients with advanced non-small cell lung cancer. Methods: One hundred cases of advanced non-small cell lung cancer admitted to our hospital were divided into 55 cases of positive group and 45 cases of negative group according to the expression of TUBB3 mRNA. Two groups of patients were treated with paclitaxel and cisplatin, Group of patients with clinical data and prognosis. Results: There was no significant difference in the clinical data between the two groups. The objective response rate, partial response rate, disease progression rate, overall survival time and tumor progression time in the negative group were better than those in the control group (P <0.05). The positive group showed no significant difference in sex, age, lymph node metastasis and TNM staging, but there was significant difference in pathological classification (squamous cell carcinoma / adenocarcinoma). Conclusion: TUBB3 mRNA negative expression in patients treated with paclitaxel combined with cisplatin can significantly prolong the survival time of patients.